EORTC 1325-MG/Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow-up
29 May 2020
Sustained long term survival benefit with adjuvant ipilimumab in patients with high risk stage III melanoma
1 Jun 2019
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
8 Jan 2018
EORTC study published in NEJM shows prolonged survival in stage III melanoma
8 Oct 2016
FDA Approves Adjuvant Yervoy in Melanoma based on results of EORTC trial 18071
13 Nov 2015
Will adjuvant pembrolizumab improve recurrence-free survival for patients with high-risk Stage III melanoma?
14 Sep 2015
EORTC opens prospective registry for patients with Melanoma
12 Jun 2015
Adjuvant Ipilimumab significantly effects recurrence-free survival in patients after resection of high risk lymph node positive melanoma
20 Apr 2015
